News Medical on MSN1 天
New Alzheimer's Strategy for Amyloid Diagnostics
A research group at LMU University Hospital has investigated how Alzheimer's disease can be diagnosed more reliably in the ...
The Pharma Letter8 小时
Alector AL002 INVOKE-2 Phase II Alzheimer’s trial misses goal
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...
Medscape2 年
Validating PET Amyloid Imaging with Autopsy
Florbetapir positron emission tomography imaging of amyloid-beta showed strong correlations with autopsy measures of amyloid plaque pathology obtained within 1 year after imaging. A hallmark ...
AlphaGalileo2 天
Alzheimer’s: new strategy for amyloid diagnostics
A research group at LMU University Hospital has investigated how Alzheimer’s disease can be diagnosed more reliably in the future.
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off ...
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...
Centiloid guidelines and recommendations released for clinical context-of-use in Alzheimer ...
The members of the Amyloid imaging to prevent Alzheimer's disease (AMYPAD) have announced the publication of a perspective ...
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early ...
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...